このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Actinogen Medical 将来の成長

Future 基準チェック /06

現在、 Actinogen Medicalの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	14.9%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	05 Sep 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Aug 09

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Apr 07

We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Oct 24

Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

Jul 11

We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

Mar 27

How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Jan 07

業績と収益の成長予測

ASX:ACW - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2025	8	N/A	-9	N/A	1
6/30/2024	10	-13	-17	-17	N/A
3/31/2024	7	-14	-15	-15	N/A
12/31/2023	5	-15	-13	-13	N/A
9/30/2023	5	-13	-11	-11	N/A
6/30/2023	5	-11	-9	-9	N/A
3/31/2023	5	-11	-9	-9	N/A
12/31/2022	5	-11	-9	-9	N/A
9/30/2022	4	-10	-9	-9	N/A
6/30/2022	4	-9	-10	-10	N/A
3/31/2022	3	-8	-8	-8	N/A
12/31/2021	2	-7	-6	-6	N/A
9/30/2021	2	-6	-4	-4	N/A
6/30/2021	2	-4	-2	-2	N/A
3/31/2021	2	-4	-2	-2	N/A
12/31/2020	3	-4	-2	-2	N/A
9/30/2020	3	-4	-3	-3	N/A
6/30/2020	4	-5	-3	-3	N/A
3/31/2020	5	-6	-5	-5	N/A
12/31/2019	6	-7	-7	-7	N/A
9/30/2019	5	-8	-9	-9	N/A
6/30/2019	5	-10	-10	-10	N/A
3/31/2019	4	-10	-10	-10	N/A
12/31/2018	3	-10	-9	-9	N/A
9/30/2018	3	-8	-8	-8	N/A
6/30/2018	3	-6	-8	-8	N/A
3/31/2018	2	-6	N/A	-6	N/A
12/31/2017	2	-5	N/A	-4	N/A
9/30/2017	1	-4	N/A	-3	N/A
6/30/2017	1	-3	N/A	-1	N/A
3/31/2017	2	-4	N/A	-2	N/A
12/31/2016	3	-4	N/A	-2	N/A
9/30/2016	3	-4	N/A	-4	N/A
6/30/2016	4	-4	N/A	-5	N/A
3/31/2016	3	-5	N/A	-5	N/A
12/31/2015	1	-5	N/A	-5	N/A
9/30/2015	1	-5	N/A	-4	N/A
6/30/2015	0	-5	N/A	-4	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-2	N/A	-1	N/A
9/30/2014	0	-1	N/A	-1	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	0	0	N/A	0	N/A
12/31/2013	0	0	N/A	0	N/A
9/30/2013	0	0	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ACWの予測収益成長が貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: ACWの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: ACWの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: ACWの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: ACWの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ACWの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Actinogen Medical 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 11%

Price target increased to AU$0.15

Recent updates

Actinogen Medical Limited, Annual General Meeting, Nov 14, 2024

New major risk - Revenue and earnings growth

Actinogen Medical Limited Announces Further Positive Results on Depression in the XanCIDD Phase 2A Trial

Actinogen Medical Limited as Announces Achievement of Clinically and Statically Significant Superiority of Xanamem over Placebo on Depression in Xanacidd Phase 2A Trial

New minor risk - Market cap size

Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker

New major risk - Revenue and earnings growth

Actinogen Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial

New major risk - Share price stability

Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Actinogen Medical Limited Announces CFO Changes

AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston

New minor risk - Share price stability

Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results

New minor risk - Shareholder dilution

Actinogen Medical Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

New major risk - Financial position

Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention

We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 11%

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Ltd Announces Receipt of Agreement from US Food and Drug Administration Agrees to Six-Month Phase 2b Alzheimers Disease Trial

Actinogen Medical Limited Announces First Patient Treated in Depression and Cognitive Impairment Phase 2 Clinical Trial

Actinogen Medical Limited Announces First Patient Treated in XanaCIDD Phase 2 Depression Trial

We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely

Price target increased to AU$0.15

Independent Non-Executive Director exercised options to buy AU$180k worth of stock.

MD, CEO & Director recently bought AU$94k worth of stock

Actinogen Medical Limited Announces Positive Alzheimers Disease Clinical Results

Actinogen Medical Limited, Annual General Meeting, Nov 16, 2022

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Actinogen Medical Limited Announces Phase 2 Trials in Alzheimer's Disease and Depression

Actinogen Medical Limited Announces Phase 2 Trial Designs for AD & MDD

MD, CEO & Director recently bought AU$128k worth of stock

Actinogen Medical Limited Announces Positive XanaMIA Results for Xanamem

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Expects Top-Line Results for the XanaMIA Part A Trial to Be Available in April 1

Actinogen Medical Announces Enrolment Reach in the XanaMIA Part A Trial of 105 Participants

We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Actinogen Medical Limited Completes Global Patent Family Grant

Actinogen Medical Limited Announces First Patient Enrolled in XanaMIA Trial

Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

Actinogen Receives Positive Pre-IND FDA Advice for FXS

Actinogen Medical Receives Ethics Committee Approval for XanaMIA study

We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

Actinogen Medical Limited Appoints Steven Gourlay as CEO

MD, CEO & Director John Ketelbey has left the company

MD, CEO & Director John Ketelbey has left the company

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Wins FDA Actinogen's Drug Xanamem Rare Paediatric Disease Designation for the Treatment of Fragile X Syndrome

How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Actinogen Medical Limited Announces Two New Clinical Trials

Actinogen Medical Limited Appoints Jeff Carter as Chief Financial Officer

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘